Logo - springer
Slogan - springer

Biomedical Sciences - Cancer Research | Resistance to Immunotherapeutic Antibodies in Cancer - Strategies to Overcome Resistance

Resistance to Immunotherapeutic Antibodies in Cancer

Strategies to Overcome Resistance

Bonavida, Benjamin (Ed.)

2013, XIII, 202 p. 29 illus., 15 illus. in color.

Available Formats:

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.


(net) price for USA

ISBN 978-1-4614-7654-2

digitally watermarked, no DRM

Included Format: PDF and EPUB

download immediately after purchase

learn more about Springer eBooks

add to marked items


Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.


(net) price for USA

ISBN 978-1-4614-7653-5

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days

add to marked items

  • ​​​​​​​​​​​Summarizes common and unique features of mAbs against various cancers  
  • Explores the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs 
  • Covers the potential use of the combination treatment of mAbs with other drugs/mAbs to reverse resistance 

The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance.

Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs.

Content Level » Research

Keywords » Rituximab - antibody-drug conjugates - cancer drug resistance - mABs - monoclonal antibody

Related subjects » Cancer Research - Immunology - Molecular Medicine

Table of contents / Preface / Sample pages 

Popular Content within this publication 



Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Cancer Research.